Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
September 11th, 2019
8.1K views
This protocol provides a reliable method to establish humanized mice with both human immune system and liver cells. Dual reconstituted immunodeficient mice achieved via intrasplenic injection of human hepatocytes and CD34+ hematopoietic stem cells are susceptible to human immunodeficiency virus-1 infection and recapitulate liver damage as observed in HIV-infected patients.
Overview
This protocol provides a reliable method to establish humanized mice with both human immune system and liver cells. The dual reconstituted immunodeficient mice are susceptible to HIV-1 infection and recapitulate liver damage as observed in HIV-infected patients.
Key Study Components
Area of Science
- Neuroscience
- Immunology
- Infectious Diseases
Background
- Humanized mouse models are essential for studying human diseases.
- These models can mimic human immune responses and liver functions.
- HIV-1 infection studies require appropriate animal models to understand disease mechanisms.
- Utilizing human hematopoietic stem cells and hepatocytes enhances model relevance.
Purpose of Study
- To generate a humanized mouse model with functional human immune system and liver.
- To investigate immunopathology caused by HIV.
- To provide insights into liver damage mechanisms in HIV-infected individuals.
Methods Used
- Intrasplenic injection of human hepatocytes and CD34+ hematopoietic stem cells.
- Use of umbilical cord blood for stem cell sourcing.
- Establishment of immunodeficient mice for human cell integration.
- Assessment of susceptibility to HIV-1 infection.
Main Results
- Successful establishment of dual reconstituted immunodeficient mice.
- Demonstration of liver damage similar to that in HIV-infected patients.
- Validation of the model for studying HIV immunopathology.
- Potential for further research into therapeutic interventions.
Conclusions
- The protocol offers a robust method for creating humanized mice.
- This model is valuable for understanding HIV-related liver damage.
- Future studies can leverage this model to explore treatment options.
Frequently Asked Questions
What are humanized mice?
Humanized mice are genetically modified mice that have been engrafted with human cells, allowing them to mimic human immune responses.
Why are humanized mice important for HIV research?
They provide a relevant model to study HIV infection and its effects on human tissues, particularly the liver.
How are the humanized mice created?
By injecting human hepatocytes and CD34+ hematopoietic stem cells into immunodeficient mice.
What is the significance of using umbilical cord blood?
Umbilical cord blood is a rich source of hematopoietic stem cells, which are crucial for reconstituting the human immune system in mice.
What are the potential applications of this research?
This research can lead to better understanding of HIV pathogenesis and the development of new therapies.
Who conducted this study?
The study was conducted by Yimin Sun, Weimin Wang, and Edward Makarov from the pathology and microbiology department.
Executive Industry Relevance
The dual humanized TK-NOG mouse model enables mechanistic de-risking of HIV-associated liver pathogenesis by recapitulating human hepatocyte engraftment and immune system development. This system supports target validation and preclinical evaluation of antiviral and antiretroviral compounds in a disease-relevant context. It provides predictive confidence for translational biomarker alignment and portfolio triage in infectious disease programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses on HIV-induced liver immunopathology using human hepatocytes and immune cells.
- Operational Value: Enables functional target validation through measurable human albumin levels and immune cell reconstitution.
- Predictive Value: Supports preclinical model selection by demonstrating liver damage phenotypes comparable to HIV-infected patients.
Screening & Assay Development
- Scientific Value: Prepares validated biological systems for downstream antiviral compound screening with quantifiable human-specific albumin ELISA readouts.
- Operational Value: Standardizes engraftment assessment via monthly human albumin ELISA and immune cell flow cytometry for reproducible monitoring.
- Scalability Value: Facilitates platform reuse across hepatitis virus co-infection studies and therapeutic intervention evaluations.
Translational & Preclinical Research
- Scientific Value: Models disease-relevant liver immunopathology to bridge discovery findings with preclinical validation of HIV pathogenesis mechanisms.
- Operational Value: Enables risk-adjusted advancement decisions by monitoring human CK18+ hepatocyte depletion and CD4/CD8 ratio shifts post-infection.
- Translational Continuity: Supports evaluation of antiviral compounds in a system exhibiting physiological aspects of human liver and immune function.
Pipeline & Workflow Integration
The model integrates into the discovery continuum from target validation through lead identification to preclinical efficacy testing, particularly for HIV-associated liver disease and co-infection studies.
- Discovery Biology: Supports hypothesis testing of HIV-driven liver damage via human hepatocyte and immune cell engraftment in immunodeficient mice.
- Screening: Delivers assay readiness through quantifiable human albumin levels and immune cell profiling for compound evaluation.
- Analytics: Provides quantitative dependent variable measurements (human albumin ELISA, flow cytometry) enabling cross-condition comparison and effect size determination.
- Translational Research: Connects to preclinical continuity by modeling liver damage and immune dysregulation observed in HIV-infected patients.
- Enterprise Reuse: Serves as a reusable capability for studying hepatitis virus co-infection and antiviral drug efficacy across multiple projects.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in HIV liver pathogenesis through dual reconstitution of human liver and immune compartments.
- Operational Value: Ensures standardization and reproducibility via defined engraftment thresholds (>15% human CD45+ cells, detectable human albumin).
- Strategic Value: Improves go/no-go decisions by enabling early detection of hepatocyte depletion and immune dysregulation.
- Portfolio Impact: Informs risk-adjusted prioritization of antiviral candidates based on liver pathology mitigation in a human-relevant system.
Implementation Considerations
- Requires expertise in hematopoietic stem cell isolation, hepatocyte preparation, and murine surgical procedures.
- Depends on specialized instrumentation including flow cytometers, ELISA readers, and biosafety level two plus facilities.
- Necessitates cross-team standardization of engraftment validation protocols using human albumin ELISA and immune cell flow cytometry.
- Involves adaptation considerations for different donor sources of hepatocytes and HSPCs to maintain engraftment consistency.
- Limited by the need for treosulfan conditioning and ganciclovir administration to achieve dual reconstitution, which adds procedural complexity.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in this model?
Null hypothesis testing determines whether observed changes in human albumin levels or immune cell populations after HIV infection are statistically significant, supporting confident target validation by distinguishing true biological effects from variability in engraftment.
How does independent variable isolation fit the discovery pipeline in this model?
Isolating HIV-1 infection as the independent variable allows researchers to attribute changes in hepatocyte depletion or immune dysregulation specifically to viral effects, enabling clear mechanistic de-risking in early discovery.
What quantitative dependent variable measurements enable assessment in this model?
Human-specific albumin ELISA quantifies hepatocyte engraftment and loss, while flow cytometry measures immune cell reconstitution and HIV-induced shifts in CD4/CD8 ratios, providing quantifiable dependent variables for efficacy evaluation.
Why do replication requirements matter for cross-functional collaboration in this model?
Replication confirms consistent engraftment levels (>15% human CD45+ cells) and reproducible HIV-induced pathology across studies, ensuring reliable data sharing between discovery, preclinical, and translational teams.
What statistical analysis capabilities are required before implementation?
Teams require proficiency in comparing pre- and post-infection measurements using appropriate statistical tests to evaluate significance of albumin depletion and immune cell changes, ensuring valid interpretation of model responses.
Chapters in this video
0:04
Title
0:47
Processing of Umbilical Cord Blood and the Isolation of Human HSPCs
4:25
Preparation of Human Hepatocytes for Transplantation
5:10
Preparation for the Surgery and Instrasplenic Transplantation of Human HSPCs and Hepatocytes in Mice
6:50
HIV Infection of TK-NOG Mice and Its Effect on the Human Liver and Immune System
7:48
Results: Analysis of the Dual Humanized TK-NOG Mouse Model
9:25
Conclusion
